Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 3Leukemia 3Immunoproliferative Disorders 3Immune System Diseases 3Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Cytokine Release Syndrome 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Epstein-Barr Virus Infections 1

Interventions

siltuximab 4fludarabine 3Cyclophosphamide 3fludarabine phosphate 2Interleukin 1 Receptor Antagonist Protein 2AP 1903 reagent 2tocilizumab 1talquetamab 1axicabtagene ciloleucel 1Neuropsychological Tests 1Metoprolol 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Infliximab 1Etanercept 1Dexamethasone 1Contrast Media 1Calcium Dobesilate 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Cytokine Release Syndrome × AP 1903 reagent × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡